Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers.

Fiche publication

Date publication

octobre 2024

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GAUCHOTTE Guillaume

Tous les auteurs :
Bertrand N, Mougel R, Riley G, Bruand M, Gauchotte G, Agopiantz M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39519199

Résumé

Neurotensin (NT) is a peptide involved in digestion, neuromodulation, and cancer progression. NT and its receptors (NTR1 and SORT1 mainly) have been widely studied in oncology. Data show that NT expression is under the control of sex steroid hormones, in particular estradiol. We focused on its involvement in three main female hormone-sensitive cancers, breast, ovarian, and endometrial cancer, in a narrative review. NT, NTR1, and SORT1 are mostly expressed in these three cancers, and their involvement in oncologic processes such as proliferation and invasion seems to match, as does their impact on prognosis for most. The development of NT receptor-targeted therapies, including theranostics and radioligand treatments, presents a promising avenue for personalized cancer treatment.